Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)
Completed · Phase 1, Phase 2 · NCT05687279
Conditions: Respiratory Syncytial Virus Infection
At a glance
- Research payments reported, 2025
- $147,404
- U.S. investigators named
- 5
- Sites paid
- 4
- Planned or actual enrollment
- 80
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Tested
- RSVt Vaccine (biological), Control Group (other)
- Dates
- Started 2023-02-06; completion 2024-12-27
- Results posted
- Yes
The primary purpose of the study is to assess the shedding, transmission, and genetic stability of the live-attenuated RSVt vaccine after each intranasal vaccination (56 days apart) in infants and toddlers 6 to \< 24 months of age.
From ClinicalTrials.gov, last updated 2026-01-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi Pasteur Inc. reported $147,404 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Brandon J. Essink, M.D. Family Medicine · Creighton, NE
- Keith W. Vrbicky, M.D. OB-GYN (Obstetrics & Gynecology) · Norfolk, NE
- Carmen Colon-tarbal, M.D. Pediatrics · San Juan, PR
- Jeffrey Quinones, MD, MBA Pediatrics · Guayama, PR
- Nicolas Rosario Matos, M.D. Pediatrics · Bayamon, PR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Research Investigator Group Llc $52,874
- Clinical Research Puerto Rico,inc $45,449
- Velocity Clinical Research,inc $32,000
- Caribbean Medical Research Center Llc $17,081
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.